Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2012

View Archived Issues

Osteros Biomedica prepares for proof-of-concept MBC-11 study

Multiple studies confirm D-type cyclins as therapeutic targets in cancer

Adaptimmune presents gene-engineered autologous T cells for multiple myeloma

Immunomedics develops antibodies with potential in the therapeutic intervention of lymphoma

Gilead Sciences patents novel sodium channel blockers

French and U.S. researchers present novel Mdm2 inhibitors for cancer

Janssen submits NDA for canagliflozin/metformin combination

4SC reports interim data from phase I/II trial of resminostat

Milestone reached in DuoBody platform collaboration

Method devised to detect biomarker of idiopathic pulmonary fibrosis

Lamazym advances to phase III alpha-mannosidosis trial

FDA approves supplemental NDA for Rescula

Kyowa Hakko Kirin begins pivotal phase III mogamulizumab study in CTCL

BrainStorm Cell Therapeutics receives grant from Israel's Office of the Chief Scientist

Amgen set to acquire deCODE Genetics

FDA accepts for review NDA for vortioxetine

NIH-sponsored trial of AstraZeneca's TB candidate commences in South Africa

Safety of antimalarial tafenoquine evaluated in phase I study

Japanese scientists present novel agents for Fabry's disease

Matrivax Research & Development Corp. patents new pneumococcal vaccines

New orexin receptor antagonists prepared by Taisho Pharmaceutical

Bayer submits MAA to EMA for prostate cancer treatment

U.S. researchers synthesize novel autophagy inhibitors

AstraZeneca reports on OSKIRA-4 phase IIb fostamatinib study

ISIS-TTRRx receives fast track designation from FDA

Insero Health completes phase Ib study of INS-001

FDA accepts for review macitentan NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.